Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Y. H. Chen; S. N. Chen; R. I. Lien; C. P. Shih; A. N. Chao; K. J. Chen; Y. S. Hwang; N. K. Wang; Y. P. Chen; K. H. Lee; C. C. Chuang; T. L. Chen; C. C. Lai; W. C. Wu

doi:10.1038/eye.2014.172

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Y. H. Chen, S. N. Chen, R. I. Lien, C. P. Shih, A. N. Chao, K. J. Chen, Y. S. Hwang, N. K. Wang, Y. P. Chen, K. H. Lee, C. C. Chuang, T. L. Chen, C. C. Lai, W. C. Wu^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

57 Scopus citations

Abstract

Purpose To evaluate the refractive outcomes in children treated after intravitreal injection of bevacizumab (IVB) for retinopathy of prematurity (ROP).Methods A retrospective, bi-centre study of 34 patients (64 eyes) was conducted. The patients were divided into three groups, patients received intravitreal IVB (IVB group), patients received combined IVB and laser treatment (IVB+Laser group), or patients received lens-sparing vitrectomy (IVB+LSV group). Cycloplegic refraction and axial length (AXL) were evaluated at 2 years old.ResultsThe prevalences of myopia and high myopia were 47.5 and 10.0% in the IVB group, respectively, which were lower than those in the IVB+Laser (82.4 and 29.4%) and IVB+LSV (all 100%) groups (P=0.001 and P<0.001). The prevalences of emmetropia in the IVB group, IVB+Laser group, and IVB+LSV group were 50, 5.9, and 0% (P=0.001). The AXL were similar among all groups. Conclusions At the 2-year follow-up, severe ROP patients treated with IVB alone were more likely to remain emmetropic and had lower prevalences of myopia and high myopia. The development of high myopia in severe ROP patients could not be explained by AXL changes but may be associated with abnormalities in the anterior segment.

Original language	English
Pages (from-to)	1080-1087
Number of pages	8
Journal	Eye (Basingstoke)
Volume	28
Issue number	9
DOIs	https://doi.org/10.1038/eye.2014.172
State	Published - 11 09 2014
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2014 Macmillan Publishers Limited All rights reserved.

Access to Document

10.1038/eye.2014.172

Cite this

Chen, Y. H., Chen, S. N., Lien, R. I., Shih, C. P., Chao, A. N., Chen, K. J., Hwang, Y. S., Wang, N. K., Chen, Y. P., Lee, K. H., Chuang, C. C., Chen, T. L., Lai, C. C., & Wu, W. C. (2014). Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Basingstoke), 28(9), 1080-1087. https://doi.org/10.1038/eye.2014.172

@article{94a60788d06a4deab00d4f74a231e80b,

title = "Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes",

abstract = "Purpose To evaluate the refractive outcomes in children treated after intravitreal injection of bevacizumab (IVB) for retinopathy of prematurity (ROP).Methods A retrospective, bi-centre study of 34 patients (64 eyes) was conducted. The patients were divided into three groups, patients received intravitreal IVB (IVB group), patients received combined IVB and laser treatment (IVB+Laser group), or patients received lens-sparing vitrectomy (IVB+LSV group). Cycloplegic refraction and axial length (AXL) were evaluated at 2 years old.ResultsThe prevalences of myopia and high myopia were 47.5 and 10.0% in the IVB group, respectively, which were lower than those in the IVB+Laser (82.4 and 29.4%) and IVB+LSV (all 100%) groups (P=0.001 and P<0.001). The prevalences of emmetropia in the IVB group, IVB+Laser group, and IVB+LSV group were 50, 5.9, and 0% (P=0.001). The AXL were similar among all groups. Conclusions At the 2-year follow-up, severe ROP patients treated with IVB alone were more likely to remain emmetropic and had lower prevalences of myopia and high myopia. The development of high myopia in severe ROP patients could not be explained by AXL changes but may be associated with abnormalities in the anterior segment.",

author = "Chen, {Y. H.} and Chen, {S. N.} and Lien, {R. I.} and Shih, {C. P.} and Chao, {A. N.} and Chen, {K. J.} and Hwang, {Y. S.} and Wang, {N. K.} and Chen, {Y. P.} and Lee, {K. H.} and Chuang, {C. C.} and Chen, {T. L.} and Lai, {C. C.} and Wu, {W. C.}",

year = "2014",

month = sep,

day = "11",

doi = "10.1038/eye.2014.172",

language = "英语",

volume = "28",

pages = "1080--1087",

journal = "Eye (Basingstoke)",

issn = "0950-222X",

publisher = "Springer Nature",

number = "9",

}

TY - JOUR

T1 - Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity

T2 - 2-year outcomes

AU - Chen, Y. H.

AU - Chen, S. N.

AU - Lien, R. I.

AU - Shih, C. P.

AU - Chao, A. N.

AU - Chen, K. J.

AU - Hwang, Y. S.

AU - Wang, N. K.

AU - Chen, Y. P.

AU - Lee, K. H.

AU - Chuang, C. C.

AU - Chen, T. L.

AU - Lai, C. C.

AU - Wu, W. C.

PY - 2014/9/11

Y1 - 2014/9/11

N2 - Purpose To evaluate the refractive outcomes in children treated after intravitreal injection of bevacizumab (IVB) for retinopathy of prematurity (ROP).Methods A retrospective, bi-centre study of 34 patients (64 eyes) was conducted. The patients were divided into three groups, patients received intravitreal IVB (IVB group), patients received combined IVB and laser treatment (IVB+Laser group), or patients received lens-sparing vitrectomy (IVB+LSV group). Cycloplegic refraction and axial length (AXL) were evaluated at 2 years old.ResultsThe prevalences of myopia and high myopia were 47.5 and 10.0% in the IVB group, respectively, which were lower than those in the IVB+Laser (82.4 and 29.4%) and IVB+LSV (all 100%) groups (P=0.001 and P<0.001). The prevalences of emmetropia in the IVB group, IVB+Laser group, and IVB+LSV group were 50, 5.9, and 0% (P=0.001). The AXL were similar among all groups. Conclusions At the 2-year follow-up, severe ROP patients treated with IVB alone were more likely to remain emmetropic and had lower prevalences of myopia and high myopia. The development of high myopia in severe ROP patients could not be explained by AXL changes but may be associated with abnormalities in the anterior segment.

AB - Purpose To evaluate the refractive outcomes in children treated after intravitreal injection of bevacizumab (IVB) for retinopathy of prematurity (ROP).Methods A retrospective, bi-centre study of 34 patients (64 eyes) was conducted. The patients were divided into three groups, patients received intravitreal IVB (IVB group), patients received combined IVB and laser treatment (IVB+Laser group), or patients received lens-sparing vitrectomy (IVB+LSV group). Cycloplegic refraction and axial length (AXL) were evaluated at 2 years old.ResultsThe prevalences of myopia and high myopia were 47.5 and 10.0% in the IVB group, respectively, which were lower than those in the IVB+Laser (82.4 and 29.4%) and IVB+LSV (all 100%) groups (P=0.001 and P<0.001). The prevalences of emmetropia in the IVB group, IVB+Laser group, and IVB+LSV group were 50, 5.9, and 0% (P=0.001). The AXL were similar among all groups. Conclusions At the 2-year follow-up, severe ROP patients treated with IVB alone were more likely to remain emmetropic and had lower prevalences of myopia and high myopia. The development of high myopia in severe ROP patients could not be explained by AXL changes but may be associated with abnormalities in the anterior segment.

UR - http://www.scopus.com/inward/record.url?scp=84927170791&partnerID=8YFLogxK

U2 - 10.1038/eye.2014.172

DO - 10.1038/eye.2014.172

M3 - 文章

C2 - 25104736

AN - SCOPUS:84927170791

SN - 0950-222X

VL - 28

SP - 1080

EP - 1087

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

IS - 9

ER -

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this